apremilast — CareFirst (Caremark)

Initial criteria

• Member with moderate to severe immunotherapy-related psoriasis and psoriasiform diseases
• Member has had an inadequate response to medium or higher potency topical corticosteroids OR has an intolerance or contraindication to medium or higher potency topical corticosteroids
• Medication not used concomitantly with any other biologic drug or targeted synthetic drug for the same indication
• Prescribed by or in consultation with a dermatologist, hematologist, or oncologist

Reauthorization criteria

• Member achieves or maintains a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition

Approval duration

12 months